Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma [0.03%]
Wenxin Xu,Brian I Rini,Laurence Albiges et al.
Wenxin Xu et al.
Recurrence after nephrectomy in high-risk localized renal cell carcinoma is common, but the genomic and transcriptomic differences between primary and recurrent tumors are not well understood. In the IMmotion010 trial, patients were randomi...
Re: Fecal Microbiota Transplantation plus Pembrolizumab and Axitinib in Metastatic Renal Cell Carcinoma: The Randomized Phase 2 TACITO Trial [0.03%]
粪便微生物移植联合派姆单抗和阿昔替尼治疗转移性肾细胞癌的Ⅱ期随机TACITO试验
Yuntao Yao,Yifan Liu,Yuanan Li et al.
Yuntao Yao et al.
Re: Antonio Franco, Francesco Ditonno, Celeste Manfredi, et al. Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.004 [0.03%]
关于安东尼奥·弗朗科、弗朗西斯科·迪托诺、切莱斯特·曼弗雷迪等人的系统回顾和最小侵袭手术治疗良性前列腺增生梗阻的功能性和性结局的汇总分析。欧洲泌尿外科杂志。在线发表。https://doi.org/10.1016/j.eururo.2025.09.004
Francesco Montorsi,Giuseppe Rosiello,Giorgio Gandaglia
Francesco Montorsi
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. 2026 [0.03%]
小松久晴, Tsukamoto T, Kakehi Y等。对于第二经尿道切除术后阴性的高分级T1膀胱癌，积极监测与卡介苗灌注的对比：JCOG1019随机非劣效性III期临床试验结果。Eur Urol. 2026
David D&#x;Andrea,Francesco Soria,Paolo Gontero et al.
David D&#x;Andrea et al.
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-Grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008 [0.03%]
小林克朗，塚本拓也，角英之等。对于第二次经尿道切除术后为阴性的高危T1期膀胱癌患者，主动监测与卡介苗膀胱灌注的非劣效性随机III期JCOG1019试验。Eur Urol. 在线发表。http://dx.doi.org/10.1016/j.eururo.2026.01.008
Andrea Piccolini,Marco Paciotti,Nicolò M Buffi
Andrea Piccolini
Performance of [89Zr]girentuximab PET/CT in Predicting the Presence of Any Renal Malignancy: A Reanalysis of the ZIRCON Trial [0.03%]
[89Zr]girentuximab-PET/CT预测肾癌的再分析：来自ZIRCON试验的结果
Aboubacar Kaba,Pratik Kanabur,Jeremie Calais et al.
Aboubacar Kaba et al.
Carbonic anhydrase IX (CAIX) is a cell surface protein expressed in over 90% of clear cell renal cell carcinoma (ccRCC), driven by hypoxia or Von-Hippel Lindau (VHL) loss. The phase 3 ZIRCON trial evaluated [89Zr]girentuximab, a CAIX-target...
Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-Controlled POISE-3 Trial [0.03%]
氨甲环酸在泌尿外科手术中安全性和有效性的研究：POISE-3国际、随机和双盲对照试验的结果分析
Kari A O Tikkinen,Maura Marcucci,Alex L E Halme et al.
Kari A O Tikkinen et al.
Background and objective: Perioperative bleeding is common. Evidence for tranexamic acid (TXA) in urology remains limited and conflicting, and major urologic guidelines provide no recommendations. In an a priori planned a...
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008 [0.03%]
小田孝弘(Kazuhiro Oda)、津久amoto(Tsukamoto)、角英行(Hideo Kakehi)等。对于二次经尿道膀胱肿瘤切除术后无残留的高危T1期膀胱癌，密切监测是否劣于卡介苗(BCG)膀胱内灌注?——JCOG1019非劣效性随机III期临床试验
Niyati Lobo,Roberto Contieri,Laura Mertens et al.
Niyati Lobo et al.
Summary Paper on the 2026 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms [0.03%]
2026年欧洲泌尿外科协会非神经源性男性下尿路症状管理指南概要论文
Michael Baboudjian,Massimiliano Creta,Nikolaos Pyrgidis et al.
Michael Baboudjian et al.
Context: The European Association of Urology (EAU) male lower urinary tract symptoms (MLUTS) Guideline Panel has updated its evidence-based guidelines and recommendations 2026 for the management of MLUTS. ...
Practice Guideline
European urology. 2026 Apr 16:S0302-2838(26)02056-7. DOI:10.1016/j.eururo.2026.03.020 2026